Takeda (TAK) announced that the European Commission approved Adcetris in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on April 25, the company noted.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide
- Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint
- Veeva price target raised to $300 from $270 at Needham
- Takeda Reports Changes in Subsidiaries and Associates as of May 28, 2025
- Takeda Announces CEO Succession and Advocates for Healthcare Reforms